Characterization and clinical relevance of a new complement-fixing antibod-anti-m8-in patients with primary biliary cirrhosis
- 1 July 1986
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 6 (4) , 553-559
- https://doi.org/10.1002/hep.1840060402
Abstract
A new complement-fixing antimitochondrial antibody-anti-M8-was detected in patients with primary biliary cirrhosis. Anti-M8 was only found in association with anti-M2, however, not all anti-M2 positive patients had anti-M8. Thus, among 66 anti-M2 positive patients, 29 were also positive for anti-M8, whereas sera from patients who had the complement-fixing anti-M2 and anti-M4 antibodies in parallel always strongly reacted with the M8 antigen. This group was previously described as mixed form. The M8 antigen was isolated either from human liver mitochondria or pig kidney microsomes and could be clearly distinguished from the M4 antigen. In contrast to M4, M8 was trypsin sensitive and banded at sucrose densities from 1.16 to 1.24, while M4 was found at densities from 1.08 to 1.14. Like M4, the M8 antigen also co-purified with outer mitochondrial membranes. Fifty-three patients with primary biliary cirrhosis have been followed over a period of up to 16 years and were classified according to their complement-fixing antimitochondrial antibody profile. At the time of the first diagnosis, 95% of 31 patients being anti-M2 positive, but anti-M8 negative (antimitochondrial antibody Profile I) were in Stage I or II. In contrast, only 61% of 13 patients being anti-M2 and anti-M8 positive (antimitochondrial antibody Profile II) and 44% of 9 patients with anti-M2, anti-M8 and anti-M4 in parallel (antimitochondrial antibody Profile III) belonged to Stage I or II. At the end of the observation period, only 24% of patients with antimitochondrial antibody Profile I (anti-M8 negative) had reached Stage III or IV, while 75% of patients with antimitochondrial antibody Profile II or III (anti-M8 positive) had a progression to Stage III or IV. It is concluded that the presence of complement-fixing anti-M8 antibody may herald a more progressive course of primary biliary cirrhosis.This publication has 29 references indexed in Scilit:
- Asymptomatic primary biliary cirrhosisGastroenterology, 1985
- Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patientsGastroenterology, 1985
- Use of ATPase-associated antigen (M2) for detection of antimitochondrial antibodies in primary biliary cirrhosis by fluorometric immunoassayJournal of Immunological Methods, 1983
- ATPASE-ASSOCIATED ANTIGEN (M2): MARKER ANTIGEN FOR SEROLOGICAL DIAGNOSIS OF PRIMARY BILIARY CIRRHOSISThe Lancet, 1982
- Natural course of primary biliary cirrhosis. I. A morphological, clinical and serological analysis of 103 casesLiver International, 1982
- Serology of primary biliary cirrhosisSpringer Seminars in Immunopathology, 1980
- SEROLOGICAL CLASSIFICATION OF CHRONIC CHOLESTATIC LIVER DISEASE BY THE USE OF TWO DIFFERENT TYPES OF ANTIMITOCHONDRIAL ANTIBODIESThe Lancet, 1980
- NEW ANTIBODY IN EARLY SYPHILISThe Lancet, 1970
- ENZYMATIC PROPERTIES OF THE INNER AND OUTER MEMBRANES OF RAT LIVER MITOCHONDRIAThe Journal of cell biology, 1968
- Succinate-linked diphosphopyridine nucleotide reduction in submitochondrial particlesBiochimica et Biophysica Acta, 1963